People | September 06, 2024
Amcor appoints Peter Konieczny as CEO
Konieczny has served as Interim CEO since April 2024
Konieczny has served as Interim CEO since April 2024
Pegfilgrastim is a Pegylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue Filgrastim
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
Revenue up 16.3% to Rs 5,600 crore versus Rs 4,814 crore
Revenue from operations stood at Rs. 313.4 crore during Q1 FY25
Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues
Our centers are performing as expected or even better
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
Q1 Consolidated operating profit Up 8.3%; revenue grows 7% to Rs 3,349 crore
Strong topline growth driven by solid performance across key brands.
Subscribe To Our Newsletter & Stay Updated
